Skip to main content
Top
Published in: Diabetologia 4/2010

01-04-2010 | Article

Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study

Authors: S.-M. Ruchat, T. Rankinen, S. J. Weisnagel, T. Rice, D. C. Rao, R. N. Bergman, C. Bouchard, L. Pérusse

Published in: Diabetologia | Issue 4/2010

Login to get access

Abstract

Aims/hypothesis

Exercise training improves glucose homeostasis, but large inter-individual differences are reported, suggesting a role of genetic factors. We investigated whether variants either confirmed or newly identified as diabetes susceptibility variants through genome-wide association studies (GWAS) modulate changes in phenotypes derived from an IVGTT in response to an endurance training programme.

Methods

We analysed eight polymorphisms in seven type 2 diabetes genes (CDKAL1 rs7756992; CDKN2A and CDKN2B rs10811661 and rs564398; HHEX rs7923837; IGF2BP2 rs4402960; KCNJ11 rs5215; PPARG rs1801282; and TCF7L2 rs7903146) in a maximum of 481 sedentary, non-diabetic white individuals, who participated in a 20-week endurance training programme. Associations were tested between the variants and changes in IVGTT-derived phenotypes.

Results

The only evidence of association with training response was found with PPARG rs1801282 (Pro12Ala). We observed that Ala carriers experienced greater increase in overall glucose tolerance (Δglucose disappearance index Ala/Ala 0.22 ± 0.22, Pro/Ala 0.14 ± 0.06, Pro/Pro 0.004 ± 0.03; p = 0.0008), glucose effectiveness (Ala/Ala 0.28 ± 0.41, Pro/Ala 0.44 ± 0.14, Pro/Pro 0.09 ± 0.06; p = 0.004), acute insulin response to glucose (Ala/Ala 64.21 ± 37.73, Pro/Ala −11.92 ± 40.30, Pro/Pro −46.30 ± 14.70; p = 0.03) and disposition index (Ala/Ala 551.8 ± 448.5, Pro/Ala 534.6 ± 218.3, Pro/Pro −7.44 ± 88.18; p = 0.003).

Conclusions/interpretation

Compared with Pro/Pro individuals, PPARG Ala carriers experienced greater improvements in glucose and insulin metabolism in response to regular endurance training. However, we did not find evidence of association between type 2 diabetes susceptibility variants recently identified through GWAS and glucose homeostasis response to exercise. Our results extend those of previous studies showing that Ala carriers appear to be more responsive to beneficial health effects of lifestyle interventions.
Literature
1.
2.
go back to reference Madden SG, Loeb SJ, Smith CA (2008) An integrative literature review of lifestyle interventions for the prevention of type II diabetes mellitus. J Clin Nurs 17:2243–2256CrossRefPubMed Madden SG, Loeb SJ, Smith CA (2008) An integrative literature review of lifestyle interventions for the prevention of type II diabetes mellitus. J Clin Nurs 17:2243–2256CrossRefPubMed
3.
go back to reference Praet SF, van Loon LJ (2007) Optimizing the therapeutic benefits of exercise in type 2 diabetes. J Appl Physiol 103:1113–1120CrossRefPubMed Praet SF, van Loon LJ (2007) Optimizing the therapeutic benefits of exercise in type 2 diabetes. J Appl Physiol 103:1113–1120CrossRefPubMed
4.
go back to reference Yates T, Khunti K, Bull F, Gorely T, Davies MJ (2007) The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia 50:1116–1126CrossRefPubMed Yates T, Khunti K, Bull F, Gorely T, Davies MJ (2007) The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia 50:1116–1126CrossRefPubMed
5.
go back to reference Boule NG, Weisnagel SJ, Lakka TA et al (2005) Effects of exercise training on glucose homeostasis: the HERITAGE Family Study. Diabetes Care 28:108–114CrossRefPubMed Boule NG, Weisnagel SJ, Lakka TA et al (2005) Effects of exercise training on glucose homeostasis: the HERITAGE Family Study. Diabetes Care 28:108–114CrossRefPubMed
6.
go back to reference Lakka TA, Rankinen T, Weisnagel SJ et al (2004) Leptin and leptin receptor gene polymorphisms and changes in glucose homeostasis in response to regular exercise in nondiabetic individuals: the HERITAGE family study. Diabetes 53:1603–1608CrossRefPubMed Lakka TA, Rankinen T, Weisnagel SJ et al (2004) Leptin and leptin receptor gene polymorphisms and changes in glucose homeostasis in response to regular exercise in nondiabetic individuals: the HERITAGE family study. Diabetes 53:1603–1608CrossRefPubMed
7.
go back to reference Lakka TA, Rankinen T, Weisnagel SJ et al (2003) A quantitative trait locus on 7q31 for the changes in plasma insulin in response to exercise training: the HERITAGE Family Study. Diabetes 52:1583–1587CrossRefPubMed Lakka TA, Rankinen T, Weisnagel SJ et al (2003) A quantitative trait locus on 7q31 for the changes in plasma insulin in response to exercise training: the HERITAGE Family Study. Diabetes 52:1583–1587CrossRefPubMed
8.
go back to reference Teran-Garcia M, Rankinen T, Rice T et al (2007) Variations in the four and a half LIM domains 1 gene (FHL1) are associated with fasting insulin and insulin sensitivity responses to regular exercise. Diabetologia 50:1858–1866CrossRefPubMed Teran-Garcia M, Rankinen T, Rice T et al (2007) Variations in the four and a half LIM domains 1 gene (FHL1) are associated with fasting insulin and insulin sensitivity responses to regular exercise. Diabetologia 50:1858–1866CrossRefPubMed
9.
go back to reference Teran-Garcia M, Santoro N, Rankinen T et al (2005) Hepatic lipase gene variant −514C>T is associated with lipoprotein and insulin sensitivity response to regular exercise: the HERITAGE Family Study. Diabetes 54:2251–2255CrossRefPubMed Teran-Garcia M, Santoro N, Rankinen T et al (2005) Hepatic lipase gene variant −514C>T is associated with lipoprotein and insulin sensitivity response to regular exercise: the HERITAGE Family Study. Diabetes 54:2251–2255CrossRefPubMed
10.
go back to reference Florez JC (2008) Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab 93:4633–4642CrossRefPubMed Florez JC (2008) Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008. J Clin Endocrinol Metab 93:4633–4642CrossRefPubMed
11.
go back to reference Florez JC, Jablonski KA, Sun MW et al (2007) Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 92:1502–1509CrossRefPubMed Florez JC, Jablonski KA, Sun MW et al (2007) Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 92:1502–1509CrossRefPubMed
12.
go back to reference Brito EC, Lyssenko V, Renstrom F et al (2009) Previously associated type 2 diabetes variants may interact with physical activity to modify the risk of impaired glucose regulation and type 2 diabetes: a study of 16,003 Swedish adults. Diabetes 58:1411–1418CrossRefPubMed Brito EC, Lyssenko V, Renstrom F et al (2009) Previously associated type 2 diabetes variants may interact with physical activity to modify the risk of impaired glucose regulation and type 2 diabetes: a study of 16,003 Swedish adults. Diabetes 58:1411–1418CrossRefPubMed
13.
go back to reference Lindi VI, Uusitupa MI, Lindstrom J et al (2002) Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51:2581–2586CrossRefPubMed Lindi VI, Uusitupa MI, Lindstrom J et al (2002) Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51:2581–2586CrossRefPubMed
14.
go back to reference Adamo KB, Sigal RJ, Williams K, Kenny G, Prud'homme D, Tesson F (2005) Influence of Pro12Ala peroxisome proliferator-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes. Diabetologia 48:1503–1509CrossRefPubMed Adamo KB, Sigal RJ, Williams K, Kenny G, Prud'homme D, Tesson F (2005) Influence of Pro12Ala peroxisome proliferator-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes. Diabetologia 48:1503–1509CrossRefPubMed
15.
go back to reference Kahara T, Takamura T, Hayakawa T et al (2003) PPARgamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism 52:209–212CrossRefPubMed Kahara T, Takamura T, Hayakawa T et al (2003) PPARgamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism 52:209–212CrossRefPubMed
16.
go back to reference Weiss EP, Kulaputana O, Ghiu IA et al (2005) Endurance training-induced changes in the insulin response to oral glucose are associated with the peroxisome proliferator-activated receptor-gamma2 Pro12Ala genotype in men but not in women. Metabolism 54:97–102CrossRefPubMed Weiss EP, Kulaputana O, Ghiu IA et al (2005) Endurance training-induced changes in the insulin response to oral glucose are associated with the peroxisome proliferator-activated receptor-gamma2 Pro12Ala genotype in men but not in women. Metabolism 54:97–102CrossRefPubMed
17.
go back to reference Reinehr T, Friedel S, Mueller TD, Toschke AM, Hebebrand J, Hinney A (2008) Evidence for an influence of TCF7L2 polymorphism rs7903146 on insulin resistance and sensitivity indices in overweight children and adolescents during a lifestyle intervention. Int J Obes (Lond) 32:1521–1524CrossRef Reinehr T, Friedel S, Mueller TD, Toschke AM, Hebebrand J, Hinney A (2008) Evidence for an influence of TCF7L2 polymorphism rs7903146 on insulin resistance and sensitivity indices in overweight children and adolescents during a lifestyle intervention. Int J Obes (Lond) 32:1521–1524CrossRef
18.
go back to reference Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250CrossRefPubMed Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250CrossRefPubMed
19.
go back to reference Moore AF, Jablonski KA, McAteer JB et al (2008) Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 57:2503–2510CrossRefPubMed Moore AF, Jablonski KA, McAteer JB et al (2008) Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 57:2503–2510CrossRefPubMed
20.
go back to reference Bouchard C, Leon AS, Rao DC, Skinner JS, Wilmore JH, Gagnon J (1995) The HERITAGE family study. Aims, design, and measurement protocol. Med Sci Sports Exerc 27:721–729PubMed Bouchard C, Leon AS, Rao DC, Skinner JS, Wilmore JH, Gagnon J (1995) The HERITAGE family study. Aims, design, and measurement protocol. Med Sci Sports Exerc 27:721–729PubMed
21.
go back to reference Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN (2003) MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003–1015CrossRefPubMed Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN (2003) MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003–1015CrossRefPubMed
22.
go back to reference Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51(Suppl 1):S212–S220CrossRefPubMed Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51(Suppl 1):S212–S220CrossRefPubMed
23.
go back to reference Desbuquois B, Aurbach GD (1971) Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33:732–738CrossRefPubMed Desbuquois B, Aurbach GD (1971) Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33:732–738CrossRefPubMed
24.
go back to reference Wilmore JH, Despres JP, Stanforth PR et al (1999) Alterations in body weight and composition consequent to 20 wk of endurance training: the HERITAGE Family Study. Am J Clin Nutr 70:346–352PubMed Wilmore JH, Despres JP, Stanforth PR et al (1999) Alterations in body weight and composition consequent to 20 wk of endurance training: the HERITAGE Family Study. Am J Clin Nutr 70:346–352PubMed
25.
go back to reference Devlin B, Risch N (1995) A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 29:311–322CrossRefPubMed Devlin B, Risch N (1995) A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 29:311–322CrossRefPubMed
26.
go back to reference Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin–rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30:97–101CrossRefPubMed Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin–rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30:97–101CrossRefPubMed
27.
go back to reference WTCCC (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678CrossRef WTCCC (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678CrossRef
28.
go back to reference Gudmundsson J, Sulem P, Steinthorsdottir V et al (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39:977–983CrossRefPubMed Gudmundsson J, Sulem P, Steinthorsdottir V et al (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39:977–983CrossRefPubMed
29.
go back to reference Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336CrossRefPubMed Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336CrossRefPubMed
30.
go back to reference Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345CrossRefPubMed Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345CrossRefPubMed
31.
go back to reference Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885CrossRefPubMed Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885CrossRefPubMed
32.
go back to reference Steinthorsdottir V, Thorleifsson G, Reynisdottir I et al (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39:770–775CrossRefPubMed Steinthorsdottir V, Thorleifsson G, Reynisdottir I et al (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39:770–775CrossRefPubMed
33.
go back to reference Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341CrossRefPubMed Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341CrossRefPubMed
34.
go back to reference Franks PW, Mesa JL, Harding AH, Wareham NJ (2007) Gene-lifestyle interaction on risk of type 2 diabetes. Nutr Metab Cardiovasc Dis 17:104–124CrossRefPubMed Franks PW, Mesa JL, Harding AH, Wareham NJ (2007) Gene-lifestyle interaction on risk of type 2 diabetes. Nutr Metab Cardiovasc Dis 17:104–124CrossRefPubMed
35.
go back to reference Ludovico O, Pellegrini F, Di Paola R et al (2007) Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity (Silver Spring) 15:1076–1081CrossRef Ludovico O, Pellegrini F, Di Paola R et al (2007) Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity (Silver Spring) 15:1076–1081CrossRef
36.
go back to reference Tonjes A, Scholz M, Loeffler M, Stumvoll M (2006) Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29:2489–2497CrossRefPubMed Tonjes A, Scholz M, Loeffler M, Stumvoll M (2006) Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29:2489–2497CrossRefPubMed
37.
go back to reference Stumvoll M, Haring H (2002) The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51:2341–2347CrossRefPubMed Stumvoll M, Haring H (2002) The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51:2341–2347CrossRefPubMed
38.
go back to reference Deeb SS, Fajas L, Nemoto M et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287CrossRefPubMed Deeb SS, Fajas L, Nemoto M et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287CrossRefPubMed
39.
go back to reference Masugi J, Tamori Y, Mori H, Koike T, Kasuga M (2000) Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268:178–182CrossRefPubMed Masugi J, Tamori Y, Mori H, Koike T, Kasuga M (2000) Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268:178–182CrossRefPubMed
40.
go back to reference Stumvoll M, Wahl HG, Loblein K et al (2001) Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 50:876–881CrossRefPubMed Stumvoll M, Wahl HG, Loblein K et al (2001) Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 50:876–881CrossRefPubMed
41.
go back to reference Thamer C, Haap M, Volk A et al (2002) Evidence for greater oxidative substrate flexibility in male carriers of the Pro 12 Ala polymorphism in PPARgamma2. Horm Metab Res 34:132–136CrossRefPubMed Thamer C, Haap M, Volk A et al (2002) Evidence for greater oxidative substrate flexibility in male carriers of the Pro 12 Ala polymorphism in PPARgamma2. Horm Metab Res 34:132–136CrossRefPubMed
Metadata
Title
Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study
Authors
S.-M. Ruchat
T. Rankinen
S. J. Weisnagel
T. Rice
D. C. Rao
R. N. Bergman
C. Bouchard
L. Pérusse
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1630-2

Other articles of this Issue 4/2010

Diabetologia 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.